Clinical outcomes of everolimus in patients with advanced, nonfunctioning pancreatic neuroendocrine tumors: A multicenter study in Korea
Cancer Chemotherapy and Pharmacology Sep 11, 2017
Lee KJ, et al. Â The efficacy and safety of everolimus in low and intermediate grade advanced pancreatic neuroendocrine tumors (pNETs) were appraised in this study. In patients undergoing everolimus treatment for pNETs with an acceptable incidence of adverse events, World Health Organization 2010 grade was the most important determinant of progression-free survival (PFS).
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
